Literature DB >> 28165246

Ultrasound Molecular Imaging of Angiogenesis Using Vascular Endothelial Growth Factor-Conjugated Microbubbles.

Jianjun Wang1, Bin Qin1, Xucai Chen1, William R Wagner2, Flordeliza S Villanueva1.   

Abstract

Imaging of angiogenesis receptors could provide a sensitive and clinically useful method for detecting neovascularization such as occurs in malignant tumors, and responses to antiangiogenic therapies for such tumors. We tested the hypothesis that microbubbles (MB) tagged with human VEGF121 (MBVEGF) bind to the kinase insert domain receptor (KDR) in vitro and angiogenic endothelium in vivo, and that this specific binding can be imaged on a clinical ultrasound system. In this work, targeted adhesion of MBVEGF was evaluated in vitro using a parallel plate flow system containing adsorbed recombinant human KDR. There was more adhesion of MBVEGF to KDR-coated plates when the amount of VEGF121 on each MB or KDR density on the plate was increased. MBVEGF adhesion to KDR-coated plates decreased with increasing wall shear rate. On intravital microscopic imaging of bFGF-stimulated rat cremaster muscle, there was greater microvascular adhesion of MBVEGF compared to that of isotype IgG-conjugated control MB (MBCTL). To determine if MBVEGF could be used to ultrasonically image angiogenesis, ultrasound imaging was performed in mice bearing squamous cell carcinoma after intravenous injection of MBVEGF. Ultrasound videointensity enhancement in tumor was significantly higher for MBVEGF (17.3 ± 9.7 dB) compared to MBCTL (3.8 ± 4.4 dB, n = 6, p < 0.05). This work demonstrates the feasibility of targeted ultrasound imaging of an angiogenic marker using MBVEGF. This approach offers a noninvasive bedside method for detecting tumor angiogenesis and could be extended to other applications such as molecular monitoring of therapeutic angiogenesis or antiangiogenic therapies in cardiovascular disease or cancer.

Entities:  

Keywords:  VEGF; angiogenesis; cancer; inflammation; microbubble contrast agents; molecular imaging; ultrasound imaging

Mesh:

Substances:

Year:  2017        PMID: 28165246      PMCID: PMC5378155          DOI: 10.1021/acs.molpharmaceut.6b01033

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  53 in total

1.  Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.

Authors:  F Ciardiello; R Caputo; R Bianco; V Damiano; G Fontanini; S Cuccato; S De Placido; A R Bianco; G Tortora
Journal:  Clin Cancer Res       Date:  2001-05       Impact factor: 12.531

2.  Targeted ultrasound contrast agents: in vitro assessment of endothelial dysfunction and multi-targeting to ICAM-1 and sialyl Lewisx.

Authors:  Gregory E R Weller; Flordeliza S Villanueva; Eric M Tom; William R Wagner
Journal:  Biotechnol Bioeng       Date:  2005-12-20       Impact factor: 4.530

Review 3.  Drug delivery strategies for therapeutic angiogenesis and antiangiogenesis.

Authors:  Nupura S Bhise; Ron B Shmueli; Joel C Sunshine; Stephany Y Tzeng; Jordan J Green
Journal:  Expert Opin Drug Deliv       Date:  2011-02-22       Impact factor: 6.648

4.  Ultrasonic imaging of tumor angiogenesis using contrast microbubbles targeted via the tumor-binding peptide arginine-arginine-leucine.

Authors:  Gregory E R Weller; Michael K K Wong; Ruth A Modzelewski; Erxiong Lu; Alexander L Klibanov; William R Wagner; Flordeliza S Villanueva
Journal:  Cancer Res       Date:  2005-01-15       Impact factor: 12.701

5.  Optimization of ultrasound contrast agents with computational models to improve selection of ligands and binding strength.

Authors:  Timothy M Maul; Drew D Dudgeon; Michael T Beste; Daniel A Hammer; John S Lazo; Flordeliza S Villanueva; William R Wagner
Journal:  Biotechnol Bioeng       Date:  2010-12-01       Impact factor: 4.530

6.  Evaluation of a (64)Cu-labeled cystine-knot peptide based on agouti-related protein for PET of tumors expressing alphavbeta3 integrin.

Authors:  Lei Jiang; Richard H Kimura; Zheng Miao; Adam P Silverman; Gang Ren; Hongguang Liu; Peiyong Li; Sanjiv Sam Gambhir; Jennifer R Cochran; Zhen Cheng
Journal:  J Nucl Med       Date:  2010-02       Impact factor: 10.057

7.  The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis.

Authors:  Timothy D Henry; Brian H Annex; George R McKendall; Michael A Azrin; John J Lopez; Frank J Giordano; P K Shah; James T Willerson; Raymond L Benza; Daniel S Berman; C Michael Gibson; Alex Bajamonde; Amy Chen Rundle; Jennifer Fine; Edward R McCluskey
Journal:  Circulation       Date:  2003-03-18       Impact factor: 29.690

8.  Ovarian volume measurements in mice with high-resolution ultrasonography.

Authors:  Andrej Lyshchik; Stephen B Hobbs; Arthur C Fleischer; Dineo Khabele; Deok-Soo Son; John C Gore; Ronald R Price
Journal:  J Ultrasound Med       Date:  2007-10       Impact factor: 2.153

9.  Microbubbles targeted to intercellular adhesion molecule-1 bind to activated coronary artery endothelial cells.

Authors:  F S Villanueva; R J Jankowski; S Klibanov; M L Pina; S M Alber; S C Watkins; G H Brandenburger; W R Wagner
Journal:  Circulation       Date:  1998-07-07       Impact factor: 29.690

10.  Recombinant canstatin inhibits VEGF-A-induced lymphangiogenesis and metastasis in an oral squamous cell carcinoma SCC-VII animal model.

Authors:  Jeon Hwang-Bo; Jong-Hwa Park; Mun Gyeong Bae; In Sik Chung
Journal:  Cancer Med       Date:  2016-09-20       Impact factor: 4.452

View more
  6 in total

1.  Endoscopic Ultrasound and Related Technologies for the Diagnosis and Treatment of Pancreatic Disease - Research Gaps and Opportunities: Summary of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.

Authors:  Linda S Lee; Dana K Andersen; Reiko Ashida; William R Brugge; Mimi I Canto; Kenneth J Chang; Suresh T Chari; John DeWitt; Joo Ha Hwang; Mouen A Khashab; Kang Kim; Michael J Levy; Kevin McGrath; Walter G Park; Aatur Singhi; Tyler Stevens; Christopher C Thompson; Mark D Topazian; Michael B Wallace; Sachin Wani; Irving Waxman; Dhiraj Yadav; Vikesh K Singh
Journal:  Pancreas       Date:  2017 Nov/Dec       Impact factor: 3.327

Review 2.  Hypoxia, angiogenesis, and metabolism in the hereditary kidney cancers.

Authors:  John C Chappell; Laura Beth Payne; W Kimryn Rathmell
Journal:  J Clin Invest       Date:  2019-01-07       Impact factor: 14.808

3.  Efficient targeted tumor imaging and secreted endostatin gene delivery by anti-CD105 immunoliposomes.

Authors:  Huiqin Zhuo; Baoshi Zheng; Jianming Liu; Yong Huang; Huiling Wang; Duo Zheng; Naiquan Mao; Jinyu Meng; Sufang Zhou; Liping Zhong; Yongxiang Zhao
Journal:  J Exp Clin Cancer Res       Date:  2018-03-02

4.  Increasing Doxorubicin Loading in Lipid-Shelled Perfluoropropane Nanobubbles via a Simple Deprotonation Strategy.

Authors:  Pinunta Nittayacharn; Eric Abenojar; Al De Leon; Dana Wegierak; Agata A Exner
Journal:  Front Pharmacol       Date:  2020-05-12       Impact factor: 5.810

5.  Synergic fabrication of pembrolizumab loaded doxorubicin incorporating microbubbles delivery for ultrasound contrast agents mediated anti-proliferation and apoptosis.

Authors:  Huilin Liu; Xing Li; Zihe Chen; Lianjie Bai; Ying Wang; Weiyang Lv
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.819

6.  Construction of ultrasonic nanobubbles carrying CAIX polypeptides to target carcinoma cells derived from various organs.

Authors:  Lianhua Zhu; Yanli Guo; Luofu Wang; Xiaozhou Fan; Xingyu Xiong; Kejing Fang; Dan Xu
Journal:  J Nanobiotechnology       Date:  2017-09-29       Impact factor: 10.435

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.